Maybridge Limited

Astrazeneca Ab

Kudos Pharmaceuticals Limited

Muhammad Hashim Javaid

Keith Allan Menear

Niall Morrison Barr Martin

Sylvie Gomez

Graeme Cameron Murray Smith

Frank Kerrigan

Marc Geoffrey Hummersone

Xiao-Ling Fan Cockcroft

Xiao-ling Fan Cockcroft

Ian Timothy William Matthews

Stefano Forte

Vincent Junior Ming-lai Loh

David Alan Rudge

Craig Anthony Roberts

Carlos Fenandez Lence

Naill Morrison Barr Martin

Kevin Blades

Vincent Junior Ming-Iai Loh

A compound of the formula (I): wherein:A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; Ris selected from H, Calkyl; and Ris selected from Calkyl, Cheterocyclyl and Caryl, which groups are optionally substituted; or Rand Rtogether with the carbon and oxygen atoms to which they are attached form a spiro-Coxygen-containing heterocyclic group, which is optionally substituted or fused to a Caromatic ring.

Phthalazinone derivatives

A compound of the formula (I): wherein Rrepresents one or more optional substituents on the fused cyclohexene ring; Ris selected from H and halo; Ris selected from H and optionally substituted Calkyl; and Rand Rare independently selected from H, R, C(&#x2550;O)OR, where R is optionally substituted Calkyl, optionally substituted Caryl or optionally substituted Cheterocyclyl; Rand Rtogether with the carbon atom to which they are attached may form an optionally substituted spiro-fused Ccarbocylic or heterocyclic ring.

A compound of the formula (I): wherein: where Yis selected from CH and N, Yis selected from CH and N, Yis selected from CH, CF and N; and where Q is O or S; wherein

A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRor CRR; if X&#x2550;NRthen n is 1 or 2 and if X&#x2550;CRRthen n is 1; Ris selected from the group consisting of H, optionally substituted Calkyl, Caryl, Cheterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ris selected from H, hydroxy, amino; or Rand Rmay together form a spiro-Ccycloalkyl or heterocyclyl group; Rand Rare independently selected from the group consisting of hydrogen and Calkyl, or when X is CRR, R, R, R, Rand R, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; Ris selected from H and halo; and Het is selected from: where Yis selected from CH and N, Yis selected from CH and N, Yis selected from CH, CF and N, where only one or two of Y, Yand Ycan be N; and where Q is O or S.

A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRor CRR; if X=NRthen n is 1 or 2 and if X=CRRthen n is 1; Ris selected from the group consisting of H, optionally substituted Calkyl, Caryl, Cheterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ris selected from H, hydroxy, amino; or Rand Rmay together form a spiro-Ccycloalkyl or heterocyclyl group; Rand Rare independently selected from the group consisting of hydrogen and Calkyl, or when X is CRR, R, R, Rand R, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; Ris selected from H and halo; and Het is selected from: where Yis selected from CH and N, Yis selected from CH and N, Yis selected from CH, CF and N, where only one or two of Y, Yand Ycan be N; and where Q is O or S.

Growing community of inventors

Cambridge, United Kingdom

Muhammad Hashim Javaid